Trial Profile
MJR-35 phase 3 study to investigate the efficacy and safety in patients with dysmenorrhea
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Dienogest (Primary)
- Indications Dysmenorrhoea
- Focus Adverse reactions; Therapeutic Use
- Sponsors Mochida Pharmaceutical
- 01 Mar 2020 Primary endpoint (Change in dysmenorrhea score at primary evaluation period) has been met published in the Fertility and Sterility
- 01 Mar 2020 Results evaluating the efficacy and safety of DNG at 1 mg/day in patients with primary and secondary dysmenorrhea published in the Fertility and Sterility
- 05 Jun 2018 Status changed from not yet recruiting to active, no longer recruiting.